L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study

被引：0

作者：

Duell, J. ^{[1
]}

Gonzalez Barca, E. ^{[2
]}

Liberati, A. M. ^{[3
]}

Salles, G. ^{[4
]}

Gaidano, G. ^{[5
]}

Jurczak, W. ^{[6
]}

Nagy, Z. ^{[7
]}

Papajlk, T. ^{[8
,9
]}

Andre, M. ^{[10
]}

Zinzani, P. L. ^{[11
]}

Kalakonda, N. ^{[12
]}

Ambarkhane, S. ^{[13
]}

Weirather, J. ^{[13
]}

Maddocks, K. ^{[14
]}

Dreyling, M. ^{[15
]}

机构：

[1] Univ Klin Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] IDIBELL, Dept Hematol, Hosp Duran & Reynals, Inst Catala Oncol, Barcelona, Spain

[3] Azienda Osped Santa Maria, SC Oncoematol, Terni, Italy

[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Serv Hematol, Pierre Benite, France

[5] Univ Piemonte Orientale, Div Hematol, Dept Translat Med, Novara, Italy

[6] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[7] Semmelweis Univ, Dept Internal Med 1, Budapest, Hungary

[8] Palacky Univ Olomouc, Olomouc, Czech Republic

[9] Univ Hosp Olomouc, Dept Hematooncol, Olomouc, Czech Republic

[10] Catholic Univ Louvain, CHU UCL Namur, Dept Hematol, Yvoir, Belgium

[11] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[12] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England

[13] MorphoSys AG, Planegg, Germany

[14] Ohio State Univ, Dept Internal Med, Ctr Comprehens Canc, Div Hematol, Columbus, OH 43210 USA

[15] LMU, Univ Hosp, Med Klin & Poliklin 3, Munich, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P260

引用

页码：68 / 68

页数：1

共 50 条

[21] Subgroup analyses of diffuse large B-cell lymphoma and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL)
Buske, C.
Jurczak, W.
Zinzani, P. L.
Gaidano, G.
Goy, A.
Provencio, M.
Nagy, Z.
Robak, T.
Maddocks, K.
Ambarkhane, S.
Winderlich, M.
Endell, J.
Blum, K. A.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 72 - 72
[22] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Zhang, Huilai
Cheng, Ying
Yang, Haiyan
Zhang, Liling
Zou, Liqun
Guo, Ye
Cao, Junning
Huang, Huiqiang
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Lyu, Jiaoyan
Fang, Yiqian
Cohen, Aileen
Zhou, Keshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years
Duell, Johannes
Jurczak, Wojciech
Liberati, Anna Marina
Halka, Janusz
Carbo, Esther Pena
Costa, Pau Abrisqueta
Maddocks, Kami J.
Dreyling, Martin
Rosenwald, Andreas
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
BLOOD, 2022, 140 : 6596 - 6598
[24] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[25] Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin H.
Gaidano, Gianluca
Barca, Eva Gonzalez
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles A.
Nagy, Zsolt
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[26] Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
Yasenchak, Christopher
Kim, Jeong-A
Hahn, Uwe
Kim, Won-Seog
Fleury, Isabelle
Laribi, Kamel
Bergua Burgues, Juan Miguel
Bouabdallah, Krimo
Forward, Nicholas
Bijou, Fontanet
MacDonald, David
Portell, Craig
Ghesquieres, Herve
Nowakowski, Grzegorz
Rustia, Evelyn
Fanale, Michelle
Jie, Fei
Bartlett, Nancy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S490 - S491
[27] Five-Year Subgroup Analysis of Tafasitamab plus Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Duell, Johannes
Abrisqueta, Pau
Dreyling, Martin
Gaidano, Gianluca
Gonzalez Barca, Eva
Jurczak, Wojciech
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S436 - S437
[28] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study
Sehn, Laurie H.
Hertzberg, Mark
Opat, Stephen
Herrera, Alex F.
Assouline, Sarit
Flowers, Christopher R.
Kim, Tae Min
McMillan, Andrew K.
Ozcan, Muhit
Safar, Violaine
Salles, Gilles
Hirata, Jamie
Yang, Annie
Musick, Lisa
Matasar, Matthew J.
BLOOD, 2022, 140 : 9464 - 9467
[30] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907

← 1 2 3 4 5 →